Identification of factors predictive of contralateral secondary hip fractures in patients after initial hip fracture - A prospective observational study [0.03%]
初次发生髋部骨折后患者同侧二次髋部骨折预测因素的识别——一项前瞻性观察研究
Shu Takata,Yusuke Uehara,Masaru Uragami et al.
Shu Takata et al.
Hip fractures are the most serious osteoporotic fractures, and patients often develop contralateral hip fractures. Various factors are reported as risks for secondary hip fracture, but risk analysis is not yet standardized. We conducted a l...
Transferrin-dependent uptake and distribution of iron in osteoclast-like cells [0.03%]
转铁蛋白依赖的铁在破骨细胞样细胞中的摄取和分布
Silvia Dolder,Romina Cabra,Jonas Zaugg et al.
Silvia Dolder et al.
Iron is an essential micro component and is involved in numerous critical cellular processes and in energy production. While its roles in oxygen transport and in oxidative phosphorylation are well documented, it remains to be elucidated, wh...
Uncoupled bone remodeling drives myeloma bone disease in Vk*MYC mouse model of multiple myeloma [0.03%]
脱偶联骨重建驱动多发性骨髓瘤小鼠模型中的骨髓瘤骨病
Clarissa Schmal,Marija K Simic,Ya Xiao et al.
Clarissa Schmal et al.
Multiple myeloma (MM), the second-most frequent hematologic malignancy, is caused by the neoplastic expansion of clonal plasma cells. Up to 80% of MM patients develop myeloma bone disease (MMBD), a hallmark of which is the development of os...
Effects of high-dose methotrexate on bone metabolism: A narrative literature review [0.03%]
高剂量甲氨蝶呤对骨代谢影响的文献综述
Anton Sokhan,Markus A Hartmann,Stéphane Blouin et al.
Anton Sokhan et al.
Methotrexate (MTX) play an important role in oncology, where it is used in high-dose therapy regimens. However, its associated dose-dependent toxicity, including MTX-osteopathy, poses a serious clinical problem, particularly in pediatric on...
Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential [0.03%]
磷二酯酶抑制剂在骨骼疾病治疗中的新兴作用：机制及再定位潜力的全面综述
Vlad-Constantin Ursachi,Jan Horak,Bohumil Fafilek
Vlad-Constantin Ursachi
Skeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis represent major global health burdens with limited therapeutic innovation. Inhibitors of phosphodiesterases (PDEs), enzymes that regulate the intracellular le...
Fracture prediction using 3D-DXA-finite element based femoral strength: a prospective study in postmenopausal women [0.03%]
基于3D-DXA-有限元的股骨强度骨折预测：绝经后妇女的前瞻性研究
Yvan Gugler,Philippe Zysset,Serge Ferrari et al.
Yvan Gugler et al.
Although areal bone mineral density (aBMD) measured by DXA is a good predictor of fractures, nearly half of low-trauma fractures occur in individuals without osteoporosis (T-score > -2.5 SD). This study investigated whether femoral strength...
Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis [0.03%]
儿童原发性骨质疏松症患者成功停用地诺单抗治疗病例报告
Athanasios D Anastasilakis,Polyzois Makras,Stergios A Polyzos et al.
Athanasios D Anastasilakis et al.
Treatment of a 13.5-year-old boy with severe primary osteoporosis and multiple vertebral deformities with denosumab (Dmab) 60 mg subcutaneously every 3 months for 30 months, resulted in significant clinical, radiologic and densitometric imp...
Case Reports
Bone reports. 2026 Feb 6:29:101904. DOI:10.1016/j.bonr.2026.101904 2026
Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study [0.03%]
Romosozumab一年后皮质骨变化的评估：来自一项HR-pQCT探索性研究的见解
María Belén Zanchetta,Mariana Gonzalez-Pernas,Fernando Jerkovich et al.
María Belén Zanchetta et al.
Purpose: To describe changes in bone microarchitecture after 6 and 12 months of romosozumab (ROMO), identify responders based on cortical thickness (Ct.Th) increase at the distal radius (≥3% at 12 months), and explore fa...
Joanna Veres,Eduardo A C Almeida,Jeannie Bailey et al.
Joanna Veres et al.
The unique mechanical unloading induced by spaceflight is associated with a very high incidence rate of chronic back pain and general degradation of tissues associated with the spinal column (i.e., bone, skeletal muscle, intervertebral disc...
Effectiveness of romosozumab following prior raloxifene treatment in primary osteoporosis: An observational study [0.03%]
一项观察性研究：Romosozumab治疗绝经后女性骨质疏松症的疗效优于Raloxifene
Kazuaki Mineta,Toshihiko Nishisho,Masahiko Okada et al.
Kazuaki Mineta et al.
Romosozumab is an anti-sclerostin antibody that increases bone formation and decreases bone resorption. It has been available for patients at high risk of osteoporotic fractures in Japan since 2019. The aim of this study was to clarify the ...